2018
The Impact of a Rigorous Quality Program on 3D Echocardiography Data Quality in an International Multisite Randomized Trial
Crowley AL, Yow E, Rabineau D, Norris C, White J, Daubert MA, Velazquez EJ, Barnhart H, Krucoff MW, Rao SV, Douglas PS. The Impact of a Rigorous Quality Program on 3D Echocardiography Data Quality in an International Multisite Randomized Trial. JACC Cardiovascular Imaging 2018, 11: 1918-1920. PMID: 30121272, DOI: 10.1016/j.jcmg.2018.05.024.Peer-Reviewed Original Research
2010
Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve
Taekman J, Stafford-Smith M, Velazquez E, Wright M, Phillips-Bute B, Pfeffer M, Sellers M, Pieper K, Newman M, Van de Werf F, Diaz R, Leimberger J, Califf R. Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve. BMJ Quality & Safety 2010, 19: 405. PMID: 20702441, PMCID: PMC3258507, DOI: 10.1136/qshc.2008.028605.Peer-Reviewed Original ResearchMeSH KeywordsClinical ProtocolsGuideline AdherenceHumansLearning CurveMulticenter Studies as TopicRandomized Controlled Trials as TopicRetrospective StudiesConceptsAcute myocardial infarctionMyocardial infarctionClinical trial researchLearning curvePatient rankMulticentre trialSlow enrollmentAcademic research organizationsPatient deathClinical trialsPatientsTrial conductTrial researchClinical researchPatient safetyPatient ordersTrialsInfarctionValsartanFirst yearDeathRecruitment ratesSimilar patternStart dateSafety
2006
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Reed SD, McMurray JJ, Velazquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, Committees and Investigators F. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2006, 152: 500-508. PMID: 16923421, DOI: 10.1016/j.ahj.2006.02.032.Peer-Reviewed Original ResearchConceptsHigh-risk patientsAcute myocardial infarctionMyocardial infarctionReperfusion therapyBaseline characteristicsVALIANT trialLeft ventricular systolic dysfunctionTime of MIAcute Myocardial Infarction trialSafety of captoprilMyocardial Infarction trialPatient baseline characteristicsUse of aspirinVentricular systolic dysfunctionProportion of patientsCare of patientsEvidence-based therapiesMultivariable regression modelsSystolic dysfunctionHeart failureTrial populationKey treatmentPatientsInternational trialInternational guidelinesContemporary performance of surgical ventricular restoration procedures: Data from the Society of Thoracic Surgeons' National Cardiac Database
Hernandez AF, Velazquez EJ, Dullum MK, O'Brien SM, Ferguson TB, Peterson ED. Contemporary performance of surgical ventricular restoration procedures: Data from the Society of Thoracic Surgeons' National Cardiac Database. American Heart Journal 2006, 152: 494-499. PMID: 16923420, DOI: 10.1016/j.ahj.2006.01.016.Peer-Reviewed Original ResearchConceptsSurgical ventricular restorationNational Cardiac DatabaseThoracic Surgeons National Cardiac DatabaseSVR procedureCardiac DatabaseSurgical ventricular restoration proceduresAdverse procedural outcomesVentricular restoration proceduresCombined end pointSevere mitral insufficiencyLeft ventricular dysfunctionCongestive heart failureInsulin-dependent diabetesStatus of surgeryCombined deathMajor morbidityOperative mortalityVentricular dysfunctionBaseline characteristicsOperative riskRenal failureCoronary diseaseHeart failureMajor complicationsOperative outcomes
2004
Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction
Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor C, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. Circulation 2004, 110: 1572-1578. PMID: 15364810, DOI: 10.1161/01.cir.0000142047.28024.f2.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCohort StudiesComorbidityDiabetes ComplicationsDiabetes MellitusDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansLife TablesMaleMedical RecordsMiddle AgedMulticenter Studies as TopicMyocardial InfarctionProportional Hazards ModelsRandomized Controlled Trials as TopicRiskStrokeTetrazolesTime FactorsTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionMyocardial infarctionCardiovascular eventsDiabetes mellitusAdverse outcomesAcute Myocardial Infarction trialPoor long-term outcomesMajor cardiovascular eventsMyocardial Infarction trialHigh-risk patientsRisk of deathLong-term outcomesRisk of mortalityBaseline characteristicsDiabetic statusComorbid conditionsMetabolic abnormalitiesPrior diagnosisPoor prognosisNew diagnosisDiabetesPatientsMellitusOutcomesInfarction
2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau J, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM, Investigators F. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal Of Heart Failure 2003, 5: 537-544. PMID: 12921816, DOI: 10.1016/s1388-9842(03)00112-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin Receptor AntagonistsCaptoprilDouble-Blind MethodFemaleGlyceraldehyde-3-Phosphate DehydrogenasesHeart FailureHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPeptide FragmentsRandomized Controlled Trials as TopicTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsAcute Myocardial Infarction trialAngiotensin receptor blockadeMyocardial Infarction trialHeart failureMyocardial infarctionACEI trialsRenin-angiotensin system blockadePlacebo-controlled trialVentricular systolic dysfunctionActive-controlled trialEvidence-based careHigh-risk populationEvidence-based therapiesCardiovascular outcomesSystem blockadeSystolic dysfunctionBaseline characteristicsStandard treatmentRepresentative cohortPatientsMI trialsTrialsValsartanACEIsLVSD
2000
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment